Originally developed for diabetes, GLP-1 medicines are becoming a cultural and commercial infrastructure spanning body image, telehealth and long-term healthcare costs.
GLP-1 drugs have moved from specialist medicine to a cultural and commercial force, reshaping conversations about weight, appetite and health. In the Substack essay that prompted this piece, Nana Oduro-Nyaning argues that the appeal of these medicines reaches far beyond diabetes treatment, touching body image, consumer behaviour and the economics of healthcare. That wider significance is grounded in the biology: GLP-1 is a gut hormone that helps regulate blood sugar, slows digestion and reduces appetite, which is why GLP-1 receptor agonists have proved useful in treating type 2 diabetes and obesity.
The modern drug class has an unusual scientific backstory. Research into the Gila monster led to the identification of exendin-4, a peptide associated with the lizard’s venom or saliva, depending on the source, that activates the GLP-1 receptor. Scientists later used that discovery to develop exenatide, the first incretin mimetic approved by the US Food and Drug Administration for type 2 diabetes. What began as an ecological curiosity in a desert reptile became the basis for a major therapeutic platform.
Much of the current boom is driven by how these medicines are being used now, not just by the patients for whom they were originally designed. The essay points to younger adults, former athletes and higher-income consumers as an expanding user base, while industry and health sites describe GLP-1 drugs as tools for weight management as well as glucose control. That broader adoption is part of a larger shift in which some consumers see prescription treatment as another route to body modification, alongside diet, exercise and cosmetic procedures.
Access, however, is uneven. Because many people seeking GLP-1s for weight loss do not meet traditional insurance rules, they often turn to cash-pay clinics, telehealth services and subscription models. That has created a parallel consumer market around the drugs, with a growing number of digital health companies acting as intermediaries between manufacturers and patients. The result is a system in which the ability to participate can depend as much on income and convenience as on medical need.
The commercial stakes are already enormous. Novo Nordisk and Eli Lilly dominate the best-known products in the class, including semaglutide and tirzepatide, and both are investing heavily in manufacturing and next-generation formulations. Their competition is not limited to the medicines themselves: the wider market now includes telehealth providers, pharmacies and weight-management platforms, all of which are trying to capture a share of the consumer relationship around long-term treatment.
What happens next may depend on whether these medicines are used briefly or for years. If patients stay on treatment long term, the financial burden could spread from individuals to insurers, employers and, ultimately, the wider healthcare system. Oduro-Nyaning’s broader argument is that GLP-1s may matter as much for the industries and habits they change as for the pounds they help patients lose. On that view, the real story is not simply a new class of drugs, but a new economic and cultural infrastructure built around appetite, health and consumption.
Disclaimer: This content is for informational purposes only and is not intended to be a substitute for professional medical judgment, advice, diagnosis, or treatment.
